LENZ Therapeutics (LENZ) Financials

LENZ Therapeutics logo
$3.82 -0.31 (-7.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.87 +0.05 (+1.31%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for LENZ Therapeutics

Annual Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-68 -71 -101 -70 -50 -82
Consolidated Net Income / (Loss)
-68 -71 -101 -70 -50 -82
Net Income / (Loss) Continuing Operations
-68 -71 -101 -70 -50 -82
Total Pre-Tax Income
-68 -71 -101 -70 -50 -82
Total Operating Income
-14 -60 -106 -72 -59 -91
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 19
Total Revenue
0.00 0.00 0.00 0.00 0.00 19
Operating Revenue
- - - - 0.00 19
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.42
Operating Cost of Revenue
- - - - 0.00 0.42
Total Operating Expenses
14 60 106 72 59 110
Selling, General & Admin Expense
4.38 23 33 13 29 91
Research & Development Expense
9.12 38 73 60 30 19
Total Other Income / (Expense), net
-55 -10 4.59 2.28 8.84 9.51
Interest & Investment Income
- - - 2.19 8.55 9.76
Other Income / (Expense), net
-55 -10 4.59 0.09 0.29 -0.24
Income Tax Expense
- - - -0.18 0.00 0.50
Basic Earnings per Share
($29.93) ($2.45) ($1.84) ($35.71) ($2.34) ($2.85)
Weighted Average Basic Shares Outstanding
2.28M 28.92M 54.87M 1.96M 21.28M 28.81M
Diluted Earnings per Share
($29.93) ($2.45) ($1.84) ($35.71) ($2.34) ($2.85)
Weighted Average Diluted Shares Outstanding
2.28M 28.92M 54.87M 1.96M 21.28M 28.81M
Weighted Average Basic & Diluted Shares Outstanding
2.28M 28.92M 58.16M 58.24M 27.54M 31.35M

Quarterly Income Statements for LENZ Therapeutics

This table shows LENZ Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-17 -10 -10 -13 -15 -15 -17 -36 -41 -32 -31
Consolidated Net Income / (Loss)
-17 -10 -10 -13 -15 -15 -17 -36 -41 -32 -31
Net Income / (Loss) Continuing Operations
-17 -10 -10 -13 -15 -15 -17 -36 -41 -32 -31
Total Pre-Tax Income
-17 -10 -10 -13 -15 -14 -17 -36 -41 -32 -31
Total Operating Income
-16 -14 -13 -15 -17 -17 -19 -38 -44 -34 -33
Total Gross Profit
0.00 0.00 0.00 - 0.00 5.00 13 1.17 0.83 5.21 2.93
Total Revenue
0.00 0.00 0.00 - 0.00 5.00 13 1.59 1.90 5.49 3.38
Operating Revenue
- 0.00 0.00 - 0.00 5.00 13 - 1.90 5.49 3.38
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 0.42 1.08 0.28 0.45
Operating Cost of Revenue
- - - - 0.00 0.00 0.00 - 1.08 0.28 0.45
Total Operating Expenses
16 14 13 15 17 22 31 40 45 39 36
Selling, General & Admin Expense
5.55 7.41 6.49 9.36 11 13 28 40 45 39 36
Research & Development Expense
11 6.95 6.45 5.87 5.82 9.06 3.79 - 0.00 0.00 0.00
Total Other Income / (Expense), net
-0.56 4.10 2.73 2.57 2.31 2.45 2.19 2.57 2.65 2.26 1.95
Interest & Investment Income
0.79 2.46 2.74 2.57 2.32 2.25 2.20 2.99 2.64 2.27 1.99
Other Income / (Expense), net
-1.35 1.64 -0.01 0.01 -0.01 0.20 -0.01 -0.42 0.00 -0.01 -0.04
Income Tax Expense
- 0.00 0.00 - - 0.50 0.00 - - 0.00 0.00
Basic Earnings per Share
($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53) ($0.59) ($1.20) ($1.32) ($1.02) ($0.99)
Weighted Average Basic Shares Outstanding
4.72M 25.61M 27.17M 21.28M 27.53M 28.08M 28.54M 28.81M 31.35M 31.37M 31.42M
Diluted Earnings per Share
($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53) ($0.59) ($1.20) ($1.32) ($1.02) ($0.99)
Weighted Average Diluted Shares Outstanding
4.72M 25.61M 27.17M 21.28M 27.53M 28.08M 28.54M 28.81M 31.35M 31.37M 31.42M
Weighted Average Basic & Diluted Shares Outstanding
25.53M 27.50M 27.50M 27.54M 28.15M 28.52M 31.29M 31.35M 31.35M 31.42M 31.42M

Annual Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
20 359 -329 -9.30 -15 4.91
Net Cash From Operating Activities
-8.72 -53 -88 -60 -59 -69
Net Cash From Continuing Operating Activities
-8.72 -53 -88 -60 -59 -69
Net Income / (Loss) Continuing Operations
-68 -71 -101 -70 -50 -82
Consolidated Net Income / (Loss)
-68 -71 -101 -70 -50 -82
Depreciation Expense
0.12 0.73 2.35 0.02 0.06 0.29
Amortization Expense
- 0.00 -1.60 -1.06 -4.02 -3.41
Non-Cash Adjustments To Reconcile Net Income
60 19 20 1.41 6.09 13
Changes in Operating Assets and Liabilities, net
-0.06 -1.37 -7.30 9.41 -12 3.25
Net Cash From Investing Activities
-1.55 -5.74 -242 -30 -154 -76
Net Cash From Continuing Investing Activities
-1.55 -5.74 -242 -30 -154 -76
Purchase of Property, Plant & Equipment
-1.55 -5.74 -6.59 -0.03 -0.47 -0.83
Purchase of Investments
- 0.00 -406 -52 -242 -281
Sale and/or Maturity of Investments
- 0.00 170 23 88 206
Net Cash From Financing Activities
30 417 0.60 81 199 150
Net Cash From Continuing Financing Activities
30 417 0.60 81 199 150
Issuance of Common Equity
0.26 252 0.66 0.00 80 149
Other Financing Activities, net
0.00 0.03 0.02 0.20 119 1.12

Quarterly Cash Flow Statements for LENZ Therapeutics

This table details how cash moves in and out of LENZ Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
165 -116 -43 -21 2.88 15 -12 -0.22 -0.41 -0.56 6.35
Net Cash From Operating Activities
-24 -16 -11 -9.08 -16 -12 -8.59 -33 -34 -39 -22
Net Cash From Continuing Operating Activities
-24 -16 -11 -9.08 -16 -12 -8.51 -33 -34 -39 -23
Net Income / (Loss) Continuing Operations
-17 -10 -10 -13 -15 -15 -17 -36 -41 -32 -31
Consolidated Net Income / (Loss)
-17 -10 -10 -13 -15 -15 -17 -36 -41 -32 -31
Depreciation Expense
0.01 0.02 0.01 0.03 0.04 0.02 0.13 0.11 0.11 0.11 0.11
Amortization Expense
-0.28 -0.96 -1.36 -1.42 -1.13 -0.89 -0.78 -0.61 -0.32 -0.13 -0.04
Non-Cash Adjustments To Reconcile Net Income
1.99 1.60 2.19 1.65 2.64 2.85 3.55 3.88 4.71 4.50 4.28
Changes in Operating Assets and Liabilities, net
-9.01 -6.20 -1.21 3.33 -2.97 1.43 5.30 -0.50 3.41 -11 4.06
Net Cash From Investing Activities
18 -98 -62 -12 19 -0.41 -4.33 -90 33 38 29
Net Cash From Continuing Investing Activities
18 -98 -62 -12 19 -0.41 -4.33 -90 33 38 29
Purchase of Investments
0.00 - -84 -47 -33 -58 -56 -133 -16 -7.37 -9.10
Sale and/or Maturity of Investments
18 13 22 35 52 58 52 43 49 45 38

Annual Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
23 402 322 70 215 306
Total Current Assets
21 382 275 67 212 301
Cash & Equivalents
20 377 48 35 20 25
Short-Term Investments
- 0.00 220 31 189 267
Accounts Receivable
- - - - 0.00 0.33
Inventories, net
- - - - 0.00 2.94
Prepaid Expenses
1.29 4.76 7.14 1.45 2.77 5.80
Plant, Property, & Equipment, net
1.46 6.51 23 0.05 0.65 1.19
Total Noncurrent Assets
0.00 14 24 3.08 2.74 3.28
Other Noncurrent Operating Assets
0.00 14 8.59 3.08 2.74 3.28
Total Liabilities & Shareholders' Equity
23 402 322 70 215 306
Total Liabilities
32 18 26 20 11 22
Total Current Liabilities
32 12 13 19 10 21
Accounts Payable
0.63 2.45 2.61 5.71 4.26 4.17
Accrued Expenses
1.89 1.52 2.59 13 6.15 17
Total Noncurrent Liabilities
0.32 5.79 13 1.18 0.81 0.35
Other Noncurrent Operating Liabilities
0.32 5.79 13 1.18 0.81 0.35
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
-65 384 296 -93 204 284
Total Preferred & Common Equity
-65 384 296 -93 204 284
Preferred Stock
0.00 0.00 0.00 - 0.00 0.00
Total Common Equity
-65 384 296 -93 204 284
Common Stock
5.18 525 540 2.53 349 511
Retained Earnings
-71 -141 -242 -95 -145 -227
Accumulated Other Comprehensive Income / (Loss)
- 0.00 -1.05 0.01 0.20 0.24

Quarterly Balance Sheets for LENZ Therapeutics

This table presents LENZ Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
287 266 217 203 224 201 217 211 273 237 210
Total Current Assets
251 239 217 199 221 198 214 207 268 233 207
Cash & Equivalents
129 183 200 84 41 23 38 25 25 24 31
Short-Term Investments
118 51 13 112 176 171 172 177 234 196 167
Accounts Receivable
- - - - - - - - 0.34 0.44 0.91
Inventories, net
- - - - - - - 0.95 3.50 4.12 4.76
Prepaid Expenses
2.88 4.78 3.28 3.12 3.48 3.77 3.97 3.88 6.14 8.72 3.92
Plant, Property, & Equipment, net
18 13 0.05 0.16 0.37 0.93 1.17 1.26 1.10 1.00 0.64
Total Noncurrent Assets
18 15 0.60 3.13 2.93 2.47 2.56 2.45 3.07 2.31 2.21
Other Noncurrent Operating Assets
18 15 0.60 3.13 2.93 2.47 2.56 2.45 3.07 2.31 2.21
Total Liabilities & Shareholders' Equity
287 266 217 203 224 201 217 211 273 237 210
Total Liabilities
63 62 19 9.72 8.73 9.24 11 17 26 17 18
Total Current Liabilities
12 13 19 8.58 7.71 8.57 10 16 26 17 18
Accounts Payable
2.72 3.75 7.13 4.41 2.76 3.66 2.85 4.32 11 6.65 5.52
Accrued Expenses
4.37 3.45 12 4.18 4.95 4.91 7.54 12 15 9.78 12
Total Noncurrent Liabilities
51 50 0.27 1.14 1.02 0.67 0.57 0.46 0.24 0.12 0.00
Other Noncurrent Operating Liabilities
51 50 0.27 1.14 1.02 0.67 0.57 0.46 0.24 0.12 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
224 204 198 193 215 192 206 194 246 219 192
Total Preferred & Common Equity
224 204 198 193 215 192 206 194 246 219 192
Preferred Stock
0.00 0.00 - - - - - - 0.00 0.00 0.00
Total Common Equity
224 204 198 193 215 192 206 194 246 219 192
Common Stock
546 548 310 315 347 352 381 385 516 520 525
Retained Earnings
-322 -344 -112 -122 -132 -160 -175 -191 -269 -301 -332
Accumulated Other Comprehensive Income / (Loss)
-0.27 -0.10 -0.00 -0.06 0.52 0.12 0.04 0.23 -0.45 -0.63 -1.06

Annual Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
- - - - - 31,289,969.00
DEI Adjusted Shares Outstanding
- - - - - 31,289,969.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - -2.62
Growth Metrics
- - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
0.00% -2.66% -43.23% 26.84% 15.12% -51.74%
EBIT Growth
0.00% -3.55% -42.81% 28.42% 19.37% -56.69%
NOPAT Growth
0.00% -347.73% -74.77% 31.44% 19.08% -55.50%
Net Income Growth
0.00% -3.49% -42.81% 30.76% 28.87% -65.02%
EPS Growth
0.00% 91.81% 24.90% -1,840.76% 93.45% -21.79%
Operating Cash Flow Growth
0.00% -506.03% -66.46% 31.37% 1.64% -16.47%
Free Cash Flow Firm Growth
0.00% 0.00% -0.77% 71.31% -123.61% -19.12%
Invested Capital Growth
0.00% 123.88% 80.10% -218.65% 66.53% -58.26%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 9.07%
EBITDA Q/Q Growth
0.00% 0.00% -6.72% -0.43% 47.32% -31.73%
EBIT Q/Q Growth
0.00% 0.00% -5.81% -0.34% 51.46% -34.94%
NOPAT Q/Q Growth
0.00% 0.00% -7.98% 2.38% 55.31% -34.22%
Net Income Q/Q Growth
0.00% 0.00% -33.54% 1.28% 56.51% -39.47%
EPS Q/Q Growth
0.00% 0.00% -132.74% -48.30% -113.64% -990.63%
Operating Cash Flow Q/Q Growth
0.00% -24.27% -8.42% 2.36% 41.14% -52.95%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% -115.89% 57.37% -47.60%
Invested Capital Q/Q Growth
0.00% 0.00% 12.10% 49.59% -160.69% 2.87%
Profitability Metrics
- - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 97.81%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -495.09%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -477.46%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -478.74%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -430.25%
Tax Burden Percent
100.00% 100.00% 100.00% 99.74% 100.00% 100.62%
Interest Burden Percent
100.06% 100.00% 100.00% 96.97% 85.33% 89.32%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
697.68% -37.81% -29.71% -40.33% -39.07% -33.63%
Cash Return on Invested Capital (CROIC)
0.00% -1,116.78% -803.61% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -35.07%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -31.52%
Return on Common Equity (ROCE)
4,656.54% -32.20% -29.71% -23.66% -17.08% -33.63%
Return on Equity Simple (ROE_SIMPLE)
104.53% -18.42% -34.11% 75.47% -24.39% 0.00%
Net Operating Profit after Tax (NOPAT)
-9.45 -42 -74 -51 -41 -64
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -334.22%
Net Nonoperating Expense Percent (NNEP)
-297.34% -14.34% -8.21% -11.03% -6.36% -7.31%
Return On Investment Capital (ROIC_SIMPLE)
- - - 54.69% -20.10% -22.44%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 2.19%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 477.46%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 97.81%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 575.27%
Earnings before Interest and Taxes (EBIT)
-68 -71 -101 -72 -58 -91
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-68 -70 -100 -73 -62 -95
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 1.88 0.65 0.00 3.89 1.76
Price to Tangible Book Value (P/TBV)
0.00 1.88 0.65 0.00 3.89 1.76
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 26.23
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 48.76 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 10.91
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
2.02 -1.06 -0.97 -1.01 -1.08 -1.03
Leverage Ratio
-2.30 1.13 1.06 1.13 1.12 1.07
Compound Leverage Factor
-2.30 1.13 1.06 1.10 0.96 0.95
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
-567.43% 0.00% 0.00% 282.94% 0.00% 0.00%
Common Equity to Total Capital
667.43% 100.00% 100.00% -182.94% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-11.32 24.18 3.41 0.17 41.74 13.08
Noncontrolling Interest Sharing Ratio
-567.43% 14.86% 0.00% 41.33% 56.28% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.66 31.44 21.11 3.63 20.36 14.23
Quick Ratio
0.62 31.04 20.57 3.55 20.09 13.81
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -79 -80 -23 -51 -61
Operating Cash Flow to CapEx
-564.47% -920.77% -1,334.24% -201,266.67% -12,690.38% -8,363.97%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-218.03 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-256.65 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.07
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 20.75
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.10
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 3,677.94
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 -3,677.94
Capital & Investment Metrics
- - - - - -
Invested Capital
-30 7.07 13 -15 -5.06 -8.01
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 -2.92
Increase / (Decrease) in Invested Capital
0.00 37 5.67 -28 10 -2.95
Enterprise Value (EV)
232 345 -90 230 585 208
Market Capitalization
196 722 193 152 794 501
Book Value per Share
($28.64) $6.61 $5.10 ($1.60) $7.42 $9.09
Tangible Book Value per Share
($28.64) $6.61 $5.10 ($1.60) $7.42 $9.09
Total Capital
-9.80 384 296 51 204 284
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-20 -377 -284 -66 -209 -292
Capital Expenditures (CapEx)
1.55 5.74 6.59 0.03 0.47 0.83
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-31 -7.38 -5.91 -17 -7.63 -12
Debt-free Net Working Capital (DFNWC)
-11 370 262 49 202 280
Net Working Capital (NWC)
-11 370 262 49 202 280
Net Nonoperating Expense (NNE)
59 28 27 19 8.74 18
Net Nonoperating Obligations (NNO)
-20 -377 -284 -66 -209 -292
Total Depreciation and Amortization (D&A)
0.12 0.73 0.75 -1.04 -3.96 -3.12
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% -63.51%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 1,468.07%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 1,468.07%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 ($2.45) ($1.84) ($2.19) ($2.34) ($2.85)
Adjusted Weighted Average Basic Shares Outstanding
0.00 58.01M 54.87M 57.02M 21.28M 28.81M
Adjusted Diluted Earnings per Share
$0.00 ($2.45) ($1.84) ($2.19) ($2.34) ($2.85)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 58.01M 54.87M 57.02M 21.28M 28.81M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($2.45) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 28.92M 58.16M 58.24M 27.54M 31.35M
Normalized Net Operating Profit after Tax (NOPAT)
-9.45 -42 -74 -51 -41 -64
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -334.22%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -427.62%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
-1,708.33 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-236.25 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-1,746.95 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-274.88 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% -0.08% -3.54% 0.00% 0.00%

Quarterly Metrics And Ratios for LENZ Therapeutics

This table displays calculated financial ratios and metrics derived from LENZ Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - - - - 31,289,969.00 31,354,394.00 31,354,394.00 31,420,343.00
DEI Adjusted Shares Outstanding
- - - - - - - 31,289,969.00 31,354,394.00 31,354,394.00 31,420,343.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - -1.15 -1.32 -1.02 -0.99
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.72% -72.93%
EBITDA Growth
-39.78% 8.90% 30.21% 34.14% -1.89% -28.33% -36.75% -137.01% -145.77% -95.16% -68.16%
EBIT Growth
-37.62% 15.09% 35.13% 38.45% 2.83% -30.99% -45.94% -155.50% -160.49% -105.22% -74.35%
NOPAT Growth
-27.52% 4.06% 34.84% 39.07% -5.24% -17.45% -45.90% -152.63% -160.68% -102.72% -74.29%
Net Income Growth
-31.40% 30.37% 45.90% 46.60% 12.19% -45.43% -63.49% -183.72% -183.80% -114.04% -85.44%
EPS Growth
45.69% 94.69% 96.05% 116.34% 84.99% -32.50% -55.26% -160.91% -149.06% -92.45% -67.80%
Operating Cash Flow Growth
-87.04% -16.79% 19.16% 56.71% 32.95% 27.14% 18.84% -263.79% -109.25% -236.40% -159.79%
Free Cash Flow Firm Growth
236.73% -229.50% -235.20% -299.87% -255.34% 61.68% 81.36% -15.75% 15.67% -123.43% -275.65%
Invested Capital Growth
-225.54% 86.31% 93.53% 66.53% 86.34% 1.12% -324.78% -58.26% -471.78% 77.33% 35.67%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 150.00% -87.30% 19.71% 188.59% -38.32%
EBITDA Q/Q Growth
74.49% 22.86% -4.70% -16.20% -8.57% 2.84% -11.57% -101.39% -12.58% 22.85% 3.86%
EBIT Q/Q Growth
76.60% 27.06% -1.84% -17.50% -11.34% 1.68% -13.47% -105.70% -13.51% 22.54% 3.60%
NOPAT Q/Q Growth
80.52% 10.79% 9.80% -17.61% -11.21% 0.44% -12.04% -103.65% -14.75% 22.57% 3.67%
Net Income Q/Q Growth
77.47% 38.41% 0.38% -23.86% -15.55% -2.00% -11.99% -114.95% -15.58% 23.07% 2.97%
EPS Q/Q Growth
-128.86% 88.67% 5.00% 618.42% -126.90% 0.00% -11.32% -103.39% -10.00% 22.73% 2.94%
Operating Cash Flow Q/Q Growth
47.82% 34.01% 33.01% 14.20% -76.79% 28.29% 25.37% -284.55% -1.69% -15.28% 42.37%
Free Cash Flow Firm Q/Q Growth
153.72% -291.94% -20.13% 44.18% -20.68% 52.65% 41.56% -246.63% 12.07% -25.45% 1.75%
Invested Capital Q/Q Growth
-0.73% 78.29% 41.27% -160.69% 58.89% -57.12% -152.30% 2.87% -48.51% 93.77% -615.79%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 73.68% 43.40% 94.90% 86.58%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% -350.54% -156.44% -2,479.91% -2,332.30% -623.51% -971.75%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% -337.14% -151.10% -2,422.10% -2,321.67% -622.89% -972.75%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -333.16% -151.21% -2,448.36% -2,321.52% -623.13% -973.82%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% -298.24% -133.60% -2,260.45% -2,182.43% -581.81% -915.16%
Tax Burden Percent
100.00% 100.00% 100.00% 100.01% 100.00% 103.47% 100.00% 100.01% 100.00% 100.01% 100.00%
Interest Burden Percent
95.48% 80.63% 78.87% 83.14% 86.29% 86.52% 88.36% 92.32% 94.01% 93.36% 93.98%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-53.79% -59.04% -54.59% -39.07% -24.47% -26.25% -28.78% -33.63% -49.71% -59.21% -72.69%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% -7.93% -12.17% -179.34% -205.69% -58.96% -57.25%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% -7.10% -10.76% -165.58% -193.37% -55.05% -53.80%
Return on Common Equity (ROCE)
-53.79% -59.04% -54.59% -17.08% -24.47% -26.25% -28.78% -33.63% -49.71% -59.21% -72.69%
Return on Equity Simple (ROE_SIMPLE)
-64.38% -63.81% -53.16% 0.00% -24.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-11 -10 -9.06 -11 -12 -12 -13 -27 -31 -24 -23
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -236.00% -105.77% -1,695.47% -1,625.17% -436.03% -680.93%
Net Nonoperating Expense Percent (NNEP)
-2.26% -0.09% -0.51% -1.45% -1.36% -1.53% -1.66% -3.58% -4.68% -3.72% -3.97%
Return On Investment Capital (ROIC_SIMPLE)
- - - -5.22% -6.17% -5.72% -6.82% -9.47% -12.53% -10.91% -12.00%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 26.32% 56.60% 5.10% 13.42%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 255.92% 220.77% 2,495.78% 2,365.07% 717.79% 1,059.34%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 181.22% 30.33% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 437.14% 251.10% 2,495.78% 2,365.07% 717.79% 1,059.34%
Earnings before Interest and Taxes (EBIT)
-17 -13 -13 -15 -17 -17 -19 -39 -44 -34 -33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-18 -14 -14 -17 -18 -18 -20 -39 -44 -34 -33
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
6.54 2.29 3.03 3.89 3.69 4.00 6.85 1.76 1.16 0.81 0.63
Price to Tangible Book Value (P/TBV)
6.54 2.29 3.03 3.89 3.69 4.00 6.85 1.76 1.16 0.81 0.63
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 164.99 75.92 26.23 13.67 8.29 9.76
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 123.07 64.37 10.91 1.36 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.01 -1.07 -1.08 -1.08 -1.04 -1.02 -1.02 -1.03 -1.03 -1.01 -1.04
Leverage Ratio
1.11 1.17 1.17 1.12 1.07 1.05 1.06 1.07 1.08 1.07 1.09
Compound Leverage Factor
1.06 0.95 0.92 0.93 0.93 0.91 0.94 0.99 1.02 1.00 1.02
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
40.67 27.34 45.00 42.40 45.71 44.90 47.12 13.65 5.84 5.10 2.49
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 56.28% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
11.47 23.23 28.63 20.36 23.09 20.54 12.69 14.23 10.40 13.55 11.66
Quick Ratio
11.29 22.85 28.16 20.09 22.64 20.15 12.39 13.81 10.03 12.81 11.17
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
16 -31 -37 -21 -25 -12 -6.92 -24 -21 -26 -26
Operating Cash Flow to CapEx
0.00% -11,875.94% -5,688.71% -6,092.62% -14,590.00% -4,795.00% -1,956.26% -86,907.89% -186,566.67% -241,956.25% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.02 0.08 0.07 0.09 0.09 0.06
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.78
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 7.50 21.47 20.75 20.76 19.78 13.02
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.20 0.37 0.45
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 467.64
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 3,677.94 1,782.25 977.52 806.01
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 -3,677.94 -1,782.25 -977.52 -338.38
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-15 -3.31 -1.94 -5.06 -2.08 -3.27 -8.25 -8.01 -12 -0.74 -5.30
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 -1.52 -3.44 -2.92 -3.00 -10.71 -1.82
Increase / (Decrease) in Invested Capital
-27 21 28 10 13 0.04 -6.30 -2.95 -9.81 2.53 2.94
Enterprise Value (EV)
1,082 245 436 585 514 615 1,126 208 29 -42 -77
Market Capitalization
1,295 441 653 794 708 825 1,329 501 287 178 121
Book Value per Share
$42.01 $7.56 $7.83 $7.42 $6.97 $7.33 $6.80 $9.09 $7.86 $6.99 $6.11
Tangible Book Value per Share
$42.01 $7.56 $7.83 $7.42 $6.97 $7.33 $6.80 $9.09 $7.86 $6.99 $6.11
Total Capital
198 193 215 204 192 206 194 284 246 219 192
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-213 -196 -217 -209 -194 -210 -202 -292 -258 -220 -197
Capital Expenditures (CapEx)
0.00 0.13 0.19 0.15 0.11 0.24 0.44 0.04 0.02 0.02 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-16 -5.46 -4.23 -7.63 -4.80 -6.43 -11 -12 -16 -3.93 -8.16
Debt-free Net Working Capital (DFNWC)
198 191 213 202 189 203 191 280 243 216 189
Net Working Capital (NWC)
198 191 213 202 189 203 191 280 243 216 189
Net Nonoperating Expense (NNE)
5.39 0.21 1.15 1.99 2.77 3.11 3.48 8.97 11 8.00 7.93
Net Nonoperating Obligations (NNO)
-213 -196 -217 -209 -194 -210 -202 -292 -258 -220 -197
Total Depreciation and Amortization (D&A)
-0.27 -0.94 -1.35 -1.40 -1.10 -0.87 -0.65 -0.50 -0.21 -0.02 0.07
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% -128.58% -65.66% -63.51% -75.39% -18.31% -65.99%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 4,064.08% 1,089.61% 1,468.07% 1,155.66% 1,006.15% 1,530.44%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 4,064.08% 1,089.61% 1,468.07% 1,155.66% 1,006.15% 1,530.44%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53) ($0.59) ($1.20) ($1.32) ($1.02) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding
4.72M 25.61M 27.17M 21.28M 27.53M 28.08M 28.54M 28.81M 31.35M 31.37M 31.42M
Adjusted Diluted Earnings per Share
($3.53) ($0.40) ($0.38) $1.97 ($0.53) ($0.53) ($0.59) ($1.20) ($1.32) ($1.02) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding
4.72M 25.61M 27.17M 21.28M 27.53M 28.08M 28.54M 28.81M 31.35M 31.37M 31.42M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.53M 27.50M 27.50M 27.54M 28.15M 28.52M 31.29M 31.35M 31.35M 31.42M 31.42M
Normalized Net Operating Profit after Tax (NOPAT)
-11 -10 -9.06 -11 -12 -12 -13 -27 -31 -24 -23
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% -236.00% -105.77% -1,695.47% -1,625.17% -436.03% -680.93%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% -288.24% -133.60% -2,260.33% -2,182.43% -581.75% -915.16%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

LENZ Therapeutics’ Q2 2026 statements show a company making progress toward commercialization, but it remains heavily loss-making and dependent on its cash and investment portfolio. Revenue increased to $5.5 million from $1.9 million in Q1 2026 and $5.0 million in Q2 2025. Gross profit was $5.2 million, representing an approximately 95% gross margin, although the company’s quarterly revenue has been volatile, including $12.5 million in Q3 2025 followed by a sharp decline in subsequent quarters.

Operating performance improved sequentially. The operating loss narrowed to $34.2 million in Q2 from $44.1 million in Q1, helped by lower selling, general and administrative expenses. Net loss also improved to $31.9 million, or $1.02 per diluted share, compared with a $41.5 million loss, or $1.32 per share, in Q1 2026. However, LENZ continues to generate substantial operating losses, and the latest income statements report no research and development expense, which may reflect changes in expense classification rather than a meaningful elimination of development spending.

The balance sheet remains relatively strong from a liquidity and leverage perspective. LENZ held $24.2 million in cash and equivalents and $195.8 million in short-term investments at June 30, 2026, for total cash and short-term investments of approximately $219.4 million. Total liabilities were only $17.3 million, compared with $219.3 million of equity. Nevertheless, liquidity declined from approximately $258.4 million at the end of Q1, while operating cash outflow rose to $38.7 million in Q2.

At the recent quarterly operating cash-burn rate, the company’s cash and short-term investments could support roughly five to six quarters of operations before considering investment income, changes in working capital, capital raises or changes in spending. This is only a rough estimate because LENZ has historically used investment purchases and maturities to manage liquidity, and quarterly cash flows have been uneven.

  • Revenue is showing commercialization progress: Q2 2026 revenue of $5.5 million was nearly three times Q1 2026 revenue and was accompanied by a gross margin of approximately 95%.
  • Sequential losses improved: The operating loss narrowed by about $10 million from Q1, while the net loss decreased from $41.5 million to $31.9 million.
  • Operating expenses declined sequentially: Selling, general and administrative expense fell to $39.4 million in Q2 from $45.0 million in Q1.
  • Liquidity remains substantial: Cash and short-term investments totaled approximately $219.4 million at the end of Q2 2026.
  • Low leverage reduces near-term financial risk: Total liabilities of $17.3 million were modest compared with $236.6 million of total assets, and the company reported no significant debt balance in the provided statements.
  • Revenue trends remain difficult to interpret: Revenue rose from $1.6 million in Q4 2025 to $5.5 million in Q2 2026, but it has fluctuated sharply, including $12.5 million in Q3 2025.
  • Investment income is supporting results: LENZ recorded $2.3 million of interest and investment income in Q2, but this is dependent on its investment balance and interest rates rather than core product sales.
  • Working capital is becoming more important: Inventory increased to $4.1 million and prepaid expenses rose to $8.7 million in Q2, consistent with preparations for commercial activity but also tying up additional capital.
  • Cash burn remains high: Operating activities consumed $38.7 million in Q2, compared with $33.6 million in Q1 and $33.0 million in Q4 2025.
  • Continued losses create financing risk: Retained earnings were negative $300.5 million at June 30, 2026, and LENZ has repeatedly relied on equity issuance, including $122.3 million of common equity issued in Q4 2025. Additional capital raises could dilute existing shareholders if operating cash flow does not improve.
11/16/26 08:38 PM ETAI Generated. May Contain Errors.

LENZ Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, LENZ Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

LENZ Therapeutics had net income of -$82.13 million at the end of 2025, a 65.0% decrease from 2024, and a 20.1% decrease since 2020. View LENZ Therapeutics' forecast to see where analysts expect LENZ Therapeutics to go next.

LENZ Therapeutics' total operating income in 2025 was -$91.14 million, based on the following breakdown:
  • Total Gross Profit: $18.67 million
  • Total Operating Expenses: $109.81 million

Over the last 5 years, LENZ Therapeutics' total revenue changed from $0.00 in 2020 to $19.09 million in 2025, a change of 1,908,800,000.0%.

In the past 13 quarters, LENZ Therapeutics' cash and equivalents has ranged from $23.04 million in Q1 2025 to $200.36 million in Q1 2024, and is currently $30.55 million as of their latest financial filing in Q3 2026.

LENZ Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2020.

Over the last 5 years, LENZ Therapeutics' book value per share changed from -28.64 in 2020 to 9.09 in 2025.



Financial statements for NASDAQ:LENZ last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners